Responses to elisrasib were seen both in patients who were naïve for KRAS G12C inhibitor therapy and in those whose disease progressed on...

Back to meeting Original

Back to meeting

AACR· @AACR · X·2026-04-20 02:12· 2026-04-20Score60

elisrasib

Reading

KRAS / RAS targeting: from platform to Phase 3

Chinese groups are not short of G12C molecules (elisrasib’s floor numbers are strong).

Body

Responses to elisrasib were seen both in patients who were naïve for KRAS G12C inhibitor therapy and in those whose disease progressed on prior KRAS G12C inhibitors. #AACR26

Heat 3 · 2 likes · 0 replies · 1 repost

Conference abstracts

CT303NCT05410145matched by 药名 cetuximab

Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1/2 study

Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque

Read the abstract →

Source: AACR · x.com